← Back to headlines
FDA to Review Savara's Resubmitted Molbreevi BLA
The FDA is set to review Savara's resubmitted Biologics License Application (BLA) for Molbreevi, indicating a new phase in the drug's regulatory process.
20 Feb, 21:42 — 20 Feb, 21:42
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Mississippi Health System Shuts Down Clinics After Ransomware Attack
3m ago
Friends Launch GoFundMe for Eric Dane's Daughters After Actor's ALS Death
22m ago
Running — the one exercise that midlife women really need to do - The Times
1h ago
Study Links Hidden Gut Virus to Increased Colorectal Cancer Risk
1h ago